Investment Thesis
AYTU BioPharma faces fundamental operational distress with a net loss of $14.2M on minimal revenue growth (+1.8% YoY), negative operating cash flow, and deteriorating profitability despite a healthy 63.7% gross margin. The massive gap between gross and operating margins indicates uncontrolled SG&A/R&D spending with unclear returns, compounded by tight liquidity and limited cash runway given current burn rates.
Strengths
- Decent gross margin of 63.7% indicates viable product economics
- Positive cash position of $26.7M provides near-term liquidity buffer
- Moderate leverage with Debt/Equity ratio of 0.27x limits financial distress risk
Risks
- Massive unprofitability: operating loss of $7.5M (18.2% margin) on $41.5M revenue
- Negative operating cash flow of $1.1M indicates core business is not self-sustaining
- Anemic revenue growth of 1.8% YoY suggests weak market position or failed commercialization
- Tight working capital with current ratio of 1.12x; cash runway vulnerable to continued burn
- Severe shareholder value destruction with ROE of -40.5% and ROA of -12.7%
- No insider activity in 90 days suggests lack of confidence from management
Key Metrics to Watch
- Operating cash flow trajectory - critical inflection point for viability
- Revenue growth acceleration - need sustained growth above 1.8% to justify R&D spending
- Operating margin improvement - path to breakeven is essential
- Cash burn rate and months of runway remaining
- Product pipeline milestones and commercial success metrics
Financial Metrics
Revenue
41.5M
Net Income
-14.2M
EPS (Diluted)
$-1.42
Free Cash Flow
-1.1M
Total Assets
111.7M
Cash
26.7M
Profitability Ratios
Gross Margin
63.7%
Operating Margin
-18.2%
Net Margin
-34.3%
ROE
-40.5%
ROA
-12.7%
FCF Margin
-2.8%
Balance Sheet & Liquidity
Current Ratio
1.12x
Quick Ratio
1.00x
Debt/Equity
0.27x
Debt/Assets
90.2%
Interest Coverage
-3.77x
Long-term Debt
9.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:43:47.557093 |
Data as of: 2026-03-31 |
Powered by Claude AI